AMILI secures $10.5 million in Series A funding

AMILI, a precision gut microbiome developer, aims to advance microbiome research and apply this knowledge to improve human health, has a gut microbiome transplant bank, and is building a multi-ethnic Asian gut microbiome database. It recently raised $10.5 million in a Series A round led by Vulcan Capital.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment